BioCentury
ARTICLE | Company News

Afraxis, ReveraGen, Viamet pharmaceuticals news

October 3, 2011 7:00 AM UTC

NIH selected four preclinical projects to fund under its Therapeutics for Rare and Neglected Diseases program. TRND will use its $24 million annual budget to provide the projects with R&D staff and laboratory resources, including funding. ...